CEO WELCOME
Leading from the front on cancer innovation Our understanding of cancers and their causes continues to progress every year and, as a result, oncology services are moving away from a generalized, one-size-fits-all approach to personalized strategies focused on more predictive, pre-emptive and preventative models. The benefits are clear, but as our knowledge and capabilities grow, so too does the daunting task of assessing, diagnosing and treating every patient as an individual. The missing link is the empowerment of healthcare systems to scale their approaches to screening and diagnosis, treatment and surgical intervention and, eventually, prevention. This is where Tecan can help. By working with our customers to scale healthcare innovation, we play a decisive role in accelerating cancer research and the development of targeted drugs, novel diagnostics and advanced medical treatments. We offer innovative sample preparation, laboratory automation, medical workflow and digital solutions that propel enabling technologies from research use to global clinical deployment. With this in mind, we recently partnered with Nature Medicine to host a select group of industry leaders, top clinicians and prominent researchers from across key areas of oncology. The two-day symposium brought together many diverse thinkers and solutions providers with a collective interest in sharing knowledge, opinions and expertise in a way that will move us all collaboratively closer to the next great achievements in oncology. We plan to carry forward that momentum with another symposium in 2024, and invite you to join us on our journey to continuously create spaces for discussions, debates and breakthroughs. While cancer is a focus area for us, this issue of the Tecan Journal also gives you the opportunity to read about some of the many other application areas where Tecan’s broad knowledge and capabilities are helping to scale up even the most complex workflows, contributing to our objective of improving peoples’ lives and health around the world.
Achim von Leoprechting CEO
2
TECAN JOURNAL 2/2023